Donezepil is a cholinesterase inhibitor of the M2 variety.
An antagonist of NMDA receptors and a potassium channel blocker make an appearance in Germany.
Although one of the recent “golden boys” of neuropathic pain treatment, with many endorsements from pain clinics, lamotrigine is not proving out.
Often misread by neurologists as mere spasticity, the heightened flexor response has been noted in the surveys, but not reported in the literature until now.
New results suggest caution in long term use of ketamine. It also raises the question of whether ketamine might be exploited to suppress sprouts at the cut ends of interrupted nerve fibers, which sprouts promote hypersensitization.
Confessions of Central Pain.
Short tech article
We are deliberately trying to keep these technical articles short for ease in reading, but that does not mean they are not important to you.
This is part II of our noting of anticancer steps that should have benefit for nerve injury pain. The work is preliminary at this point, not in human trials for pain.
We have said before that given the much larger amount of money available to cancer and heart disease, and due to the recently recognized link with inflammation in these conditions, that central pain might well be cured as a spinoff. Here is a new drug that stops Protein Kinase C.